Notably, CTSH does not exhibit pleiotropy, i.e., it does not affect other phenotypes, making it a promising therapeutic target through the suppression of its expression to reduce neuroinflammatory responses that underpin ALS pathophysiology [7,142]. Here, CTSH is linked to amyotrophic lateral sclerosis.